B2M and neoplasm: A study of 17 metastatic melanoma patients found that Beta-2 microglobulin (B2M), another essential component of the HLA class I antigen presentation machinery, was mutated, deleted or subject to LOH in 29% of patients whose tumours did not respond to immune checkpoint blocking therapy [15].